Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Myeloid 1Lymphoid 1Genitourinary 1Gastrointestinal 1CNS 1

Conditions

Lymphoma, Non-Hodgkin 2Wilms Tumor 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Rhabdoid Tumor 1Osteosarcoma 1Neuroectodermal Tumors, Primitive, Peripheral 1Neuroblastoma 1Medulloblastoma 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, T-Cell 1Lymphoma, Follicular 1Lymphoma, B-Cell 1Histiocytosis, Langerhans-Cell 1Hepatoblastoma 1Glioma 1Ependymoma 1Endometrial Neoplasms 1Endometrial Hyperplasia 1

Interventions

Magnetic Resonance Spectroscopy 10Temozolomide 9X-Rays 7Specimen Handling 7Phantoms, Imaging 7Filgrastim 6Nuclear Medicine Department, Hospital 5Cyclophosphamide 5Carboplatin 5Vorinostat 4Thiotepa 4Radiotherapy 4Peripheral Blood Stem Cell Transplantation 4Irinotecan 4Cisplatin 4Biopsy 4tipifarnib 3O(6)-benzylguanine 3HhAntag691 3veliparib 2ulixertinib 2tazemetostat 2selpercatinib 2palbociclib 2olaparib 2larotrectinib 2ivosidenib 2erdafitinib 2ensartinib 2Vincristine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Medulloblastoma × Pharmacogenomic Variants × Clear all
NCT03698994 2026-05-27

Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
20 enrolled 9 charts
CNSGastrointestinalGenitourinaryLymphoidMyeloidSarcoma

Ependymoma, Glioma, Histiocytosis, Langerhans-Cell, Lymphoma, Non-Hodgkin, Medulloblastoma, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Hepatoblastoma, Neuroectodermal Tumors, Primitive, Peripheral, Rhabdoid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡